Elucidata Stock (ELUI)

Elucidata's proprietary SaaS platform, Polly, transforms drug discovery- one curated dataset at a time. Polly delivers ML-ready biomedical molecular data for accelerated drug discovery. Hosting a rich repository of more than 230,000 multi-omic datasets, Polly curates data semi-automatically, with over 50,000 datasets added each month. The company equips data-driven drug discovery teams with a code-first SaaS platform that integrates proprietary and public biomedical molecular data for ML applications. Inspired by the FAIR guidelines described by the NIH, Polly's Data Lakes allow exclusive access to curated multi-omics data that is ready for ML workflows. Polly offers 10x faster identification of therapeutic assets with high odds of success in the clinic. It has enabled the detection of multiple validated drug targets across immunology, oncology, and metabolomic disorders. Polly supports discovery programs at Pfizer, Agios Pharmaceuticals, Genentech, and Yale and has 35+ research partners from premier biopharma companies and research labs.